Clinical Trial Update: BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 study of BMS-214662 in patients with various leukemias and myelodysplastic syndromes has completed enrollment; the document lists the diseases studied a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Acute Promyelocytic Leukemia
• Anemia with Excess Blasts
• Anemia with Excess Blasts in Transformation
• Chronic Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• BMS-214662

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Acute Promyelocytic Leukemia (M3), Blastic Phase Chronic Myelogenous Leukemia | Phase 1 | Status: COMPLETED